What does SpyGlass Pharma do?
SpyGlass Pharma develops innovative ophthalmic drug delivery systems, providing a platform designed to deliver 3 years of bimatoprost to targeted tissues for sustained treatment in eye care.
How much did they raise?
The company raised $75M in a Series D round, led by Sands Capital with participation from Gilde Healthcare, New Enterprise Associates, RA Capital, Vensana Capital, Samsara BioCapital, and Vertex Ventures HC.
What are their plans for the money?
The funds will be used to advance SpyGlass Pharma's platform through two registrational Phase III clinical trials, with plans to present follow-up data and work closely with the FDA to achieve commercial approval.
What have they achieved so far?
SpyGlass Pharma has successfully completed enrollment in a Phase I/II study and is following patients in its first-in-human study, setting the stage for its upcoming Phase III trials.
